Marinus Pharmaceuticals, Inc.

218 articles with Marinus Pharmaceuticals, Inc.

• Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

  3/22/2023

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut syndrome (LGS).

• Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/7/2023

  ZTALMY ® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - March 6, 2023

  3/6/2023

  Marinus Pharmaceuticals, Inc. today announced the grant of inducement awards to 1 new employee.

• Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter 2022 Financial Results on March 7, 2023

  2/13/2023

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the fourth quarter ended December 31, 2022 on March 7, 2023.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 10, 2023

  2/10/2023

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to 5 new employees.

• Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

  2/7/2023

  Marinus Pharmaceuticals, Inc. today announced that management will present and participate during the following conferences in February and March.

• Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors

  1/30/2023

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 09, 2023

  1/9/2023

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to two new employees.

• Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY® Net Product Revenue and Provides Business Update

  1/5/2023

  Marinus Pharmaceuticals, Inc. reported business highlights and preliminary U.S. ZTALMY® net product revenue for the fourth quarter and year ended December 31, 2022.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - December 9, 2022

  12/9/2022

  Marinus Pharmaceuticals, Inc today announced the grant of inducement awards to two new employees.

• Marinus Pharmaceuticals Announces Presentations and Investor Event at American Epilepsy Society 2022 Annual Meeting

  11/30/2022

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that ganaxolone data from three abstracts, including one late-breaking abstract, will be presented at the upcoming 2022 American Epilepsy Society (AES) Annual Meeting, which will be held December 2-6, 2022, in Nashville, TN.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - November 18, 2022

  11/18/2022

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to 3 new employees.

• Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board

  11/17/2022

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board.

• Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China

  11/17/2022

  Marinus Pharmaceuticals today announced that it has entered into a collaboration and supply agreement with Tenacia Biotechnology (Shanghai) Co., Ltd., a China-based biotechnology company focused on the development of innovative treatments for central nervous system (CNS) disorders.

• Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering

  11/8/2022

  Marinus Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 2,105,264 shares of common stock at a price of $4.749 per pre-funded warrant, for gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and offering expenses payable by Marinus.

• Marinus Pharmaceuticals Announces Proposed Public Offering - November 07, 2022

  11/7/2022

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that it has commenced an underwritten public offering of its securities.

• Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

  11/7/2022

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2022.

• Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners

  10/31/2022

  Marinus Pharmaceuticals, Inc. today announced that it has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5 million upfront in return for payments based on U.S. net sales of ganaxolone, including the recently approved ZTALMY® (ganaxolone) oral suspension CV.

• Marinus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 8, 2022

  10/25/2022

  Marinus Pharmaceuticals, Inc. today announced that it plans to release financial results for the third quarter ended September 30, 2022 before the U.S. financial market opens on November 8, 2022.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - October 14, 2022

  10/14/2022

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.